Avanos Medical, Inc. (AVNS)
USD 16.18
(-4.94%)
USD 16.18
(-4.94%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.2 Million USD | -29.19% |
| 2022 | 74 Million USD | 731.46% |
| 2021 | 8.9 Million USD | 119.31% |
| 2020 | -46.1 Million USD | 17.24% |
| 2019 | -55.7 Million USD | -11240.0% |
| 2018 | 500 Thousand USD | 101.16% |
| 2017 | -43.1 Million USD | -149.31% |
| 2016 | 87.4 Million USD | 123.14% |
| 2015 | -377.7 Million USD | -500.53% |
| 2014 | 94.3 Million USD | -58.14% |
| 2013 | 225.3 Million USD | -1.18% |
| 2012 | 228 Million USD | 8.21% |
| 2011 | 210.7 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 16.1 Million USD | 117.57% |
| 2024 Q3 | 12 Million USD | -25.47% |
| 2024 Q1 | 7.4 Million USD | -66.67% |
| 2023 Q3 | 1.2 Million USD | 157.14% |
| 2023 Q2 | -2.1 Million USD | -180.77% |
| 2023 Q1 | 2.6 Million USD | -90.08% |
| 2023 FY | 52.4 Million USD | -29.19% |
| 2023 Q4 | 22.2 Million USD | 1750.0% |
| 2022 FY | 74 Million USD | 731.46% |
| 2022 Q4 | 26.2 Million USD | 40.11% |
| 2022 Q3 | 18.7 Million USD | -1.58% |
| 2022 Q2 | 19 Million USD | 106.52% |
| 2022 Q1 | 9.2 Million USD | -63.2% |
| 2021 Q2 | -7.3 Million USD | 41.13% |
| 2021 Q4 | 25 Million USD | 594.44% |
| 2021 FY | 8.9 Million USD | 119.31% |
| 2021 Q3 | 3.6 Million USD | 149.32% |
| 2021 Q1 | -12.4 Million USD | 72.32% |
| 2020 Q2 | -1.8 Million USD | -400.0% |
| 2020 Q1 | 600 Thousand USD | 118.75% |
| 2020 Q3 | -100 Thousand USD | 94.44% |
| 2020 FY | -46.1 Million USD | 17.24% |
| 2020 Q4 | -44.8 Million USD | -44700.0% |
| 2019 Q4 | -3.2 Million USD | 82.32% |
| 2019 Q2 | -9.8 Million USD | 60.16% |
| 2019 Q3 | -18.1 Million USD | -84.69% |
| 2019 Q1 | -24.6 Million USD | -196.39% |
| 2019 FY | -55.7 Million USD | -11240.0% |
| 2018 FY | 500 Thousand USD | 101.16% |
| 2018 Q4 | -8.3 Million USD | -218.57% |
| 2018 Q3 | 7 Million USD | -20.45% |
| 2018 Q2 | 8.8 Million USD | 225.71% |
| 2018 Q1 | -7 Million USD | 94.51% |
| 2017 Q3 | 28.8 Million USD | -1.37% |
| 2017 FY | -43.1 Million USD | -149.31% |
| 2017 Q4 | -127.4 Million USD | -542.36% |
| 2017 Q2 | 29.2 Million USD | 11.03% |
| 2017 Q1 | 26.3 Million USD | 66.46% |
| 2016 Q3 | 20.9 Million USD | 18.75% |
| 2016 FY | 87.4 Million USD | 123.14% |
| 2016 Q4 | 15.8 Million USD | -24.4% |
| 2016 Q2 | 17.6 Million USD | -46.83% |
| 2016 Q1 | 33.1 Million USD | 61.46% |
| 2015 FY | -377.7 Million USD | -500.53% |
| 2015 Q4 | 20.5 Million USD | 104.44% |
| 2015 Q3 | -461.2 Million USD | -2186.88% |
| 2015 Q2 | 22.1 Million USD | -45.97% |
| 2015 Q1 | 40.9 Million USD | 70.42% |
| 2014 Q1 | 61.7 Million USD | 7.12% |
| 2014 FY | 94.3 Million USD | -58.14% |
| 2014 Q2 | -4.5 Million USD | -107.29% |
| 2014 Q4 | 24 Million USD | 83.21% |
| 2014 Q3 | 13.1 Million USD | 391.11% |
| 2013 Q2 | 56.9 Million USD | 40.49% |
| 2013 Q4 | 57.6 Million USD | -18.07% |
| 2013 Q1 | 40.5 Million USD | 0.0% |
| 2013 FY | 225.3 Million USD | -1.18% |
| 2013 Q3 | 70.3 Million USD | 23.55% |
| 2012 FY | 228 Million USD | 8.21% |
| 2011 FY | 210.7 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott Laboratories | 6.47 Billion USD | 99.935% |
| Allurion Technologies Inc. | -78.07 Million USD | 105.379% |
| Artivion, Inc. | 5.74 Million USD | 26.855% |
| Butterfly Network, Inc. | -145.61 Million USD | 102.884% |
| Butterfly Network, Inc. | -145.61 Million USD | 102.884% |
| Bio-Rad Laboratories, Inc. | 383.79 Million USD | 98.906% |
| Boston Scientific Corporation | 2.34 Billion USD | 99.821% |
| Perspective Therapeutics, Inc. | -15.18 Million USD | 127.664% |
| CONMED Corporation | 130.78 Million USD | 96.789% |
| Edwards Lifesciences Corporation | 1.53 Billion USD | 99.726% |
| Paragon 28, Inc. | -37.3 Million USD | 111.257% |
| Glaukos Corporation | -128.7 Million USD | 103.263% |
| Globus Medical, Inc. | 133.14 Million USD | 96.845% |
| Inspire Medical Systems, Inc. | -40.27 Million USD | 110.429% |
| Integer Holdings Corporation | 167.33 Million USD | 97.49% |
| Medtronic plc | 5.14 Billion USD | 99.918% |
| Nevro Corp. | -99.3 Million USD | 104.229% |
| Owlet, Inc. | -28.63 Million USD | 114.669% |
| Penumbra, Inc. | 73.55 Million USD | 94.29% |
| Vicarious Surgical Inc. | -80.66 Million USD | 105.207% |
| Smith & Nephew plc | 425 Million USD | 99.012% |
| Sonendo, Inc. | -57.74 Million USD | 107.274% |
| STERIS plc | 836.11 Million USD | 99.498% |
| Stryker Corporation | 3.88 Billion USD | 99.892% |
| Vapotherm, Inc. | -39.08 Million USD | 110.747% |
| Zimmer Biomet Holdings, Inc. | 1.27 Billion USD | 99.671% |